AINU launches new centre in Hyderabad covering various sub-specialities
The centre features four operating rooms, 34 dialysis stations and advanced robotic surgical technology, enabling complex urology and nephrology procedures with greater precision. The hospital also has eight centres of excellence, covering sub-specialities such as female urology, uro-oncology and robotic surgery, paediatric urology, reconstructive urology and andrology.
The burden of urological diseases is rising sharply in India due to lifestyle disorders such as hypertension, obesity and diabetes, coupled with increased life expectancy. 'Prostate cancer is now the second most common cancer among Indian men, growing at 2.5% annually, and 50 to 60% of men over 60 suffer from benign prostatic enlargement,' said AINU manging director Mallikarjuna.
He added that 25 years ago, urology was largely limited to treating kidney stones and enlarged prostates. Today, the scope includes advanced cancer care, complex reconstructions, paediatric interventions, female urology and robotic surgeries.
'One doctor cannot be perfect in every area, so we have created dedicated teams focused solely on one sub-speciality, performing the same surgeries repeatedly. This results in faster procedures, fewer complications, better outcomes and ultimately lower costs for patients,' he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
India's Apollo Hospitals to double AI investments, beats profit estimate
Hyderabad: India's Apollo Hospitals Enterprise plans to double its investment in artificial intelligence capabilities over the next two to three years, its CEO said, after the company beat first-quarter profit estimates on higher patient volume. The hospital chain already uses AI tools in diagnosis to read X-rays, scan reports and also in endoscopy - a medical procedure to examine the inside of the body using a camera, CEO Madhu Sasidhar told Reuters on Tuesday. Many large private hospital chains in India, like their western counterparts, are investing in AI capabilities to improve patient diagnosis and decisions related to medical procedures, among others uses. Apollo recently developed technology to read existing scan reports and predict the risk of liver fibrosis in the future, Sasidhar said. "We are also bringing some other new generation agentic AI-type tools," he said. He did not quantify the size of Apollo's existing investment in AI. Apollo, headquartered in the south Indian city of Chennai, partnered with Microsoft earlier this year to develop AI-based tools to be used in healthcare. Some of them are in early stages of testing, Sasidhar said. Indian hospital chains such as Apollo and Manipal have also been increasing their bed count for a larger share of the market, including through acquisitions of smaller hospital operators. Apollo said it is on track to add 4,370 beds over the next 3-4 years through acquisition, new hospitals and expansion of existing facilities. Its overall bed capacity is currently more than 10,000. The company's consolidated net profit rose 41.8% to 4.33 billion rupees ($49.40 million) for April-June, beating estimates of 3.86 billion rupees, according to data compiled by LSEG. While its overall occupancy rate dipped from last year, in-patient volume grew 3% and average revenue per in-patient increased by 9%, according to Apollo. Quarterly total revenue rose 15% to 58.42 billion rupees, beating estimates of 57.44 billion rupees. The company said it expects double-digit revenue growth for the current financial year.
Hans India
an hour ago
- Hans India
Organ donation should become as popular as Annadana
Tumakuru: Just as the tradition of annadana (food donation) has been deeply rooted in Indian society, organ donation too must gain widespread acceptance to bring new life to patients battling terminal illnesses, said Dr. M.R. Hulinaykar, founder and president of Shridevi Medical College. Speaking at a press conference on the occasion of World Organ Donation Day, Dr. Hulinaykar announced that Shridevi Hospital has received government approval to perform organ transplants. While kidney and corneal transplants are already being conducted, the hospital plans to soon begin liver, lung, and heart transplants with the help of a skilled team of specialists. 'The lack of awareness is the biggest reason for the shortage of organs in India,' he said, urging media, religious leaders, and social and health workers to play an active role in spreading awareness. The college plans to hold awareness camps in both urban and rural areas to educate people about the life-saving benefits of organ donation. Medical Director Dr. Raman Hulinaykar noted that as part of World Organ Donation Day, the college organised a week-long awareness campaign featuring various competitions. 'One donor can save or transform 7–8 lives,' he said, stressing the need for public participation. Shridevi Charitable Trust trustee and eye specialist Dr. Lavanya, HR head M.S. Patil, Medical Superintendent Mohan Kumar, Principal Dr. M.L. Harendra Kumar, and Dr. Yashwanth Gangayya were also present.
Fashion Value Chain
an hour ago
- Fashion Value Chain
Solo-Dex and Polymedicure Partner to Bring Opioid-Free Acute Pain Management to India and Major Asian Markets
Solo-Dex, Inc., a U.S.-based medical device innovator, and Polymedicure Ltd. (Polymed), Indias leading manufacturer of high-quality medical devices, today announced a strategic manufacturing and supply partnership to bring Solo-Dexs patented, opioid-free regional anesthesia solutions to hospitals across India for the first time. Under this agreement, Polymed will manufacture Solo-Dexs flagship product, the Fascile Continuous Peripheral Nerve Block system, in accordance with Solo-Dexs strict quality standards, for distribution across India and key global markets. The product is already approved for clinical use in the United States and Europe and is now set to support Indias expanding Enhanced Recovery After Surgery (ERAS) programs and the growth of outpatient surgical care. 'This is a game-changer for pain management in India,' said Steven Eror, CEO of Solo-Dex. 'Polymeds scale, precision, and strong regulatory framework make them the ideal manufacturing partner. Together, well deliver a transformative technology that goes far beyond suppressing pain-it blocks acute pain completely.' First-of-its-kind in India: Faster, Safer, Non-Opioid Pain Control Solo-Dexs patented device installs in under two minutes and enables continuous, localized pain relief without opioids. Unlike conventional methods that may require IV sedation and can result in patient delirium, Solo-Dex minimizes systemic drug exposure, and eliminates the need for oral opioids thereby improving patient safety, reducing recovery time, and decreasing demand on hospital resources. The technology is designed to seamlessly integrate with ERAS protocols, helping hospitals manage post-operative pain more efficiently. As Indias healthcare system increasingly embraces day surgery and outpatient models, Solo-Dex offers a solution that enhances patient throughput and satisfaction without compromising clinical outcomes. 'We are excited to be part of this international collaboration,' said Himanshu Baid, Managing Director of Polymed. 'This partnership not only brings cutting-edge pain management to Indian clinicians and patients, but also aligns with our commitment to making world-class healthcare more accessible.' Designed for Global Impact Manufacturing will take place in Polymeds ISO 13485-certified, FDA-auditable facilities, with initial orders for 100,000 units. In addition to serving India, the partnership aims to fulfill international demand across Asia, Africa, Latin America, and select European markets, with Solo-Dex overseeing global regulatory compliance and branding. 'Thanks to this agreement, Solo-Dex now has the scalable, cost-effective production capacity to meet global demand while maintaining the clinical precision and quality our technology requires,' said Eror. 'Were especially proud to collaborate with Polymed to address the worldwide need for safer, opioid-free surgical recovery.' The Solo-Dex and Polymed partnership is already engaging with leading hospital systems across India, with commercial availability expected to begin in Q4 2025. About Solo-Dex, Inc. Solo-Dex is a U.S.-based medical device company focused on opioid-free acute pain management. Its patented continuous peripheral nerve block systems enable anesthesiologists to deliver localized, long-lasting anesthesia for post-surgical recovery. Solo-Dex technology is approved for clinical use in the U.S. and EU. About Polymedicure Limited Polymed is one of Indias most trusted names in medical devices, with a portfolio of more than 125 FDA-approved and CE-marked products. With a global presence in over 100 countries, Polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-quality healthcare solutions at scale.
